MICROSCOPIC POLYANGIITIS
Clinical trials for MICROSCOPIC POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new MICROSCOPIC POLYANGIITIS trials appear
Sign up with your email to follow new studies for MICROSCOPIC POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug MT-2990 tested in rare blood vessel disease
Disease control CompletedThis early study looked at a new drug, MT-2990, in 5 people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal was to see if the drug is safe and how it affects disease activity. Researchers measured changes in symptoms, imagin…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE1 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Cheaper rituximab versions just as safe and effective for rare vasculitis?
Disease control CompletedThis study looked at 201 Canadian patients with ANCA-associated vasculitis to see if cheaper biosimilar versions of rituximab work as well as the original drug. Researchers compared disease control, side effects, and how long it took to get insurance approval for treatment. The g…
Matched conditions: MICROSCOPIC POLYANGIITIS
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Statin trial targets hidden heart risk in vasculitis patients
Disease control CompletedThis study tested whether rosuvastatin, a common cholesterol-lowering drug, could reduce early signs of artery hardening in 121 people with ANCA-associated vasculitis. Participants were in remission and received either rosuvastatin or a placebo for up to 2 years. The goal was to …
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can a Double-Dose vaccine strategy shield vulnerable vasculitis patients?
Disease control CompletedThis study tested whether giving a stronger pneumococcal vaccine schedule (either two doses close together or a single larger dose) followed by a standard booster could improve immune protection in 96 adults with ANCA-associated vasculitis who are also receiving rituximab therapy…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Rituximab shows promise in preventing vasculitis relapses
Disease control CompletedThis study tested whether rituximab, a targeted antibody therapy, is better than azathioprine, a standard immune-suppressing drug, at preventing relapses in people with ANCA-associated vasculitis. 117 patients who had achieved remission were randomly assigned to receive either ri…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Smart dosing of rituximab may keep rare blood vessel disease at bay
Disease control CompletedThis study tested two ways of giving rituximab to people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. All 166 participants were in remission and received rituximab either on a fixed schedule or only when certain blood markers (ANC…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 13:48 UTC
-
Could a tiny dose of naltrexone ease vasculitis symptoms?
Symptom relief CompletedThis study tested whether a low dose (4.5 mg) of naltrexone, a drug already used for alcoholism, can improve physical health and quality of life in people with vasculitis. Sixty participants took either the drug or a placebo daily for six weeks. The goal was to see if the drug le…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC